AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

• Clinical Improvement After the Last Injection [ Time Frame: 30 days after last treatment ] [ Designated as safety issue: No ]
• Percent Reduction From Baseline Contracture After the Last Injection [ Time Frame: 30 days after last treatment ] [ Designated as safety issue: No ]
• Change From Baseline Range of Motion After the Last Injection [ Time Frame: 30 days after last treatment ] [ Designated as safety issue: No ]
• Time to First Achieve and Maintain Clinical Success After the Last Injection [ Time Frame: First evaluation visit on which clinical success is achieved and maintained through the Day 30 evaluation ] [ Designated as safety issue: No ]
• Clinical Success After the First Injection [ Time Frame: 30 days after first treatment ] [ Designated as safety issue: No ]
• Clinical Improvement After the First Injection [ Time Frame: 30 days after first treatment ] [ Designated as safety issue: No ]
• Percent Reduction From Baseline Contracture After the First Injection [ Time Frame: 30 days after first treatment ] [ Designated as safety issue: No ]
• Change From Baseline Range of Motion After the First Injection [ Time Frame: 30 days after first treatment ] [ Designated as safety issue: No ]

• Clinical improvement of each treated joint.
• Percent reduction from baseline in contracture of each treated joint.
• Percent change from baseline in range of motion of each treated joint.
• Time to clinical success of each treated joint.
• Proportion of joints with recurrence

Study AUX-CC-858 was an open-label continuation of the double-blind Study AUX-CC-857 (NCT00528606). Subjects who complete the Day 90 visit after their initial injection in Study AUX-CC-857 (NCT00528606) entered into Study AUX-CC-858. Subjects who required further treatment in Study AUX-CC-858, either because their treated metacarpophalangeal and/or proximal interphalangeal (PIP) joints did not have a reduction in contracture to 5° or less, the cord affecting that joint received less than three injections of AA4500, or they had other eligible cords that received no treatment in AUX-CC-857 (NCT00528606), had the option to receive up to five injections of AA4500 in this extension study. Subjects requiring further treatment were followed for efficacy and safety on Days 1, 7, and 30 after each injection, with injections separated by four weeks. Follow-up visits for the determination of efficacy and safety were conducted on Day 90, Month 6, and Month 9.

This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.

Inclusion Criteria:

• Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
• Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
• Were naïve to AA4500 treatment or had received only one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in AUX-CC-857 ((NCT00528606).
• Were judged to be in good health.
• Must have participated in protocol AUX-CC-857 (NCT00528606).

Exclusion Criteria:

• Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
• Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.
• Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.